about
Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitorAntimetastatic Activity of a Preventive Cancer VaccineIn silico modeling and in vivo efficacy of cancer-preventive vaccinations.Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.Synthesis and characterization of (68)Ga-labeled curcumin and curcuminoid complexes as potential radiotracers for imaging of cancer and Alzheimer's disease.Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Complex interplay between neutral and adaptive evolution shaped differential genomic background and disease susceptibility along the Italian peninsulaVaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.Uptake of Ga-curcumin derivatives in different cancer cell lines: Toward the development of new potential 68Ga-labelled curcuminoids-based radiotracers for tumour imaging.No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis.Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.New insights into the pathogenesis of giant cell arteritis.Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.Toward the definition of immunosuppressive regimens with antitumor activity.Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas.Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.Immunological prevention of a multigene cancer syndrome.Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells.Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity.Affinity of (nat/68)Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers.HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12.Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.Increased expression of interleukin-22 in patients with giant cell arteritis.Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature.Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome.Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis.MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis.High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesisHigher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet DiseaseImmune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
P50
Q28728165-99705D92-5B01-4CE7-8C92-8D1F9A36D761Q29399455-E13FF24A-F155-4ABC-B134-F4FF94CBBB8DQ34141954-15AFD580-231B-479B-963C-D700C7B945C5Q34574879-6DE98629-9A8E-49D3-988F-A00C78957E07Q35083847-ACB4B637-A49E-43E0-B543-CEE7566A6291Q35157522-3C91AC97-6E68-48E4-9223-B9EC36A6920DQ35710332-CB15CEA6-587F-4D60-AF9F-FBABB66D573AQ37198935-03971052-EA91-4D61-8DBC-12393EB1A2ACQ37223446-B015F073-0420-421B-8D3B-3EF250AEE21CQ37691212-79A7CE1F-0B33-436C-B81A-38F3648AA7B7Q38703342-9235EEFB-17B5-41CD-AFE3-5EEEE4642AAAQ38920083-85A44ED7-37ED-44A2-A3B6-F53E016FFC45Q39289206-8A9B9DA4-849D-40F2-8395-EDB2E5DD93A3Q39289317-BE294718-65EF-4208-868D-5519D5BC561CQ39642376-6A475DB7-6E93-4950-A204-8F0F4EACEF1DQ40172818-C9C27871-A99C-4D41-99FC-4C9689DC1CB5Q40324701-A65896E2-FC8C-46FB-8C54-395406451A64Q40407750-CA8A1DFA-ED26-4AB0-8F57-B0F3175E0508Q40413679-5A5201A8-50B6-4507-B5F4-E1CE066F4849Q40427655-95C5BF5C-3CD8-4BDD-B86E-5819B41EA357Q40490598-48CE9D98-B2E5-4504-BDA9-C0B802A34083Q40583180-231222D4-2ECE-4511-9FE7-B241B349E0BCQ40594474-4905F8B1-DC99-4284-A73F-F0AC50284D54Q41191380-270A0095-D5C7-494C-A412-725060A8F8F5Q44294226-C5E9BBFB-CCFE-479B-AB9A-8EBCDF05ACFFQ44409601-FA6A22FE-956A-48FA-A27A-5E22E65D525AQ46018302-1DD51AD4-360B-41B1-AB3C-360F331B6B31Q47406818-D08F8F59-91DC-4A56-9F37-46A011091D34Q47715350-38148845-40AE-459D-BFEE-259F3C5EBD79Q47865727-17D00A32-DAD2-4940-BF9C-E7B19EA48141Q47995551-5F0FC2CF-238C-4ABE-AA68-0ACFA32A70B2Q48592090-6C1F2250-E7AD-4DAA-B04D-6CC0E6F57BAEQ51656898-3ECC4228-032D-4CE8-A1C2-DDB82CE04569Q52566930-4D13402C-D4F2-4A39-973E-4C5A20EE8672Q53118262-1261B70C-DDD0-4070-ACA0-6873C2F890D8Q53355647-CD95D1FB-E113-4BA5-8C82-42F1BA187F6EQ54702110-E8B868DD-CF54-432C-B12C-D9A86764811FQ56996550-1045E45F-C783-4475-AF71-C0CADF012258Q57492024-C70E9382-D587-4DA2-B1C5-283D4E930560Q61797742-2AC38E03-745A-4CB6-B840-1329CAFBE6AB
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefania Croci
@ast
Stefania Croci
@en
Stefania Croci
@es
Stefania Croci
@nl
type
label
Stefania Croci
@ast
Stefania Croci
@en
Stefania Croci
@es
Stefania Croci
@nl
prefLabel
Stefania Croci
@ast
Stefania Croci
@en
Stefania Croci
@es
Stefania Croci
@nl
P106
P1153
7003450132
P21
P31
P496
0000-0002-8622-0439